Boentert, Matthias
Berger, Kenneth I.
Díaz-Manera, Jordi
Dimachkie, Mazen M.
Hamed, Alaa
Riou França, Lionel
Thibault, Nathan
Shukla, Pragya
Ishak, Jack
Caro, J. Jaime http://orcid.org/0000-0001-5470-3754
Funding for this research was provided by:
Sanofi
Article History
Received: 30 November 2022
Accepted: 18 November 2023
First Online: 12 January 2024
Declarations
:
: The COMET study protocol was approved by the ethics committees or institutional review boards of the participating centers and carried out in accordance with the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice. Written informed consent was obtained from participants before any study-related procedures.
: Not applicable.
: MB reports receiving speaker honoraria from Sanofi Genzyme, Amicus, Biogen, UCB Pharma, and ITF Pharma; advisory board activities for Sanofi-Genzyme, Amicus, Pharnext, and Biogen; and financial research support from Sanofi-Genzyme and Löwenstein Medical. KIB reports board membership for AskBio, Sanofi Genzyme, Spark Therapeutics, and Takeda; and receiving consulting Fees from Amicus Therapeutics, AskBio, Sanofi Genzyme, Spark Therapeutics, Takeda, and Inventiva Pharma. JDM reports advisory board membership for Sanofi, Sarepta, Amicus, Audentes, and Lupin; consulting fees from Spark Therapeutics, Sanofi, Audentes, and Lupin; contracted research with Spark Therapeutics, Sanofi, Audentes, and Boehringer Ingelheim; intellectual property rights/patent with Boehringer Ingelheim; and travel expenses from Sanofi, Pfizer, and Amicus. MMD serves or recently served as a consultant for Amazentis, ArgenX, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, Medlink, Momenta, NuFactor, Octapharma, Priovant, RaPharma/UCB, Roivant Sciences Inc, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Abata/Third Rock, UCB Biopharma and UpToDate. MMD also received research grants or contracts or educational grants from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, The Myositis Association, UCB Biopharma/RaPharma, Viromed/Healixmith & TMA. AH and NT are employees and stockholders of Sanofi. LRF was an employee of Sanofi at the time of study conduct and holds stock in Sanofi; he is currently an employee of Aixial, a CRO working with Sanofi. PS, JI, and JJC are employed by Evidera, a consultancy that received funding from Sanofi for the work reported here.